| PIERRE FABRE MEDICAMENT Patent applications |
| Patent application number | Title | Published |
|---|
| 20120115860 | NOVEL DERIVATIVES OF ARYL--METHANONE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS - The present invention concerns compounds of general formula (1) (I) wherein R | 05-10-2012 |
| 20120088792 | Pyridin-2-YL Methylamine Derivatives for Treating Opiate Dependence - The invention concerns the use of compounds of general formula (I) | 04-12-2012 |
| 20120077777 | NGCYCLOARTANONE DERIVATIVES WITH ANTICANCER ACTIVITY - The present invention relates to a compound of following formula (I): | 03-29-2012 |
| 20120064130 | METHOD FOR IMPREGNATION WITH SUPERCRITICAL CO2 - The present invention relates to a batch method for impregnating a nonporous polymer pharmaceutical carrier with an active substance, characterised in that said method includes the following consecutive steps: a) mixing the active substance and the nonporous polymer pharmaceutical carrier, the pharmaceutical carrier being in a solid form and insoluble in supercritical CO | 03-15-2012 |
| 20120029013 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS - The present invention concerns compounds of general formula (1), where in:—-a- is a single or double bond, Ar is an aromatic group, substituted or unsubstituted, R1 and R2 each independently or together are: a hydrogen atom or C | 02-02-2012 |
| 20120022273 | PROCESS FOR THE PREPARATION OF (POLY) AMINOALKYLAMINOACETAMIDE DERIVATIVES OF EPIPODOPHYLLOTOXIN USEFUL FOR THEIR APPLICATIONS IN THERAPEUTICS AS ANTICANCER AGENT - The present invention relates to a new process for the preparation of (poly)aminoalkylaminoacetamide derivatives of epipodophyllotoxin and salts thereof, characterised in that it comprises a step of peptide coupling of 4-amino-4′-demethylepipodophyllotoxin with an amine-containing reactant having protecting groups. | 01-26-2012 |
| 20110319326 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS - The object of the present invention is benzothiazine derivatives having the capability of inhibiting 11β-HSD1 not only at an enzymatic level but also at a cell level. The compounds of the present invention are of general formula (I). Wherein notably R | 12-29-2011 |
| 20110295036 | METHOD FOR SYNTHESIS OF (1S, 2R)-MILNACIPRAN - The present invention relates to a method for synthesizing a pharmaceutically acceptable acid addition salt of (1S, 2R)-milnacipran comprising the following successive steps: (a) reaction of phenylacetonitrile and of (R)-epichlorhydrin in the presence of a base containing an alkaline metal, followed by a basic treatment, and then by an acid treatment in order to obtain a lactone; (b) reaction of said lactone with MNEt | 12-01-2011 |
| 20110262409 | COMPOSITION COMPRISING A COMBINATION OF AN ELDER EXTRACT AND A STRAIN OF L. PARACASEI, L. CASEI, L. BULGARICUS OR S. THERMOPHILUS - The invention relates to a composition comprising a combination of an elder extract ( | 10-27-2011 |
| 20110183376 | NOVEL ANTI-IGF-IR ANTIBODIES AND USES THEREOF - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 07-28-2011 |
| 20110165062 | Use of an anti-cd151 antibody for early treatment of cancer - The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the early treatment of cancer. | 07-07-2011 |
| 20110152289 | DIMERIC DERIVATIVES OF ARTEMISININ AND APPLICATION IN ANTI-CANCER THERAPY - The present invention relates to dimeric derivatives of 10-trifluoromethylated artemisinin of formula (I) below: Formula (I) and the pharmaceutically acceptable salts thereof, and also to the preparation method thereof and to the uses thereof, especially in the treatment of cancer. | 06-23-2011 |
| 20110123516 | NITROGENATED DERIVATIVES OF PANCRATISTATIN - The present invention concerns nitrogenated derivatives of narciclasine and pancratistatin of the following general formula (I) as well their pharmaceutically acceptable salts. The present invention also concerns the use of these compounds in cancer therapy as well as a method for their preparation. | 05-26-2011 |
| 20110118266 | DERIVATIVES OF TRIAZINES AND URACILS, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPEUTICS - The present invention relates to derivatives of general formula I wherein: —W represents nitrogen, —R | 05-19-2011 |
| 20110117098 | COMBINATION OF A C-MET ANTAGONIST AND AN AMINOHETEROARYL COMPOUND FOR THE TREATMENT OF CANCER - The invention also relates to a composition comprising an antibody antagonist to c-Met and an aminoheteroaryl compound, particularly as a medicament. The present invention also comprises a pharmaceutical composition comprising said anti c-Met antibody and said aminoheteroaryl compound as combination products for simultaneous, separate or sequential use. The invention relates to the use of the composition of the invention for the treatment of cancer in a mammal. | 05-19-2011 |
| 20110021589 | IMIDAZOLIC COMPOUNDS AND USE THEREOF AS ALPHA-2 ADRENERGIC RECEPTORS - The invention provides methods of treating a memory deficiency in a subject in need of such treatment, where the methods comprise administering to a subject an effective amount of a compound of formula (1): | 01-27-2011 |
| 20110015221 | PHARMACEUTICAL COMPOSITION OF VINFLUNINE WHICH IS INTENDED FOR PARENTERAL ADMINISTRATION PREPARATION METHOD THEREOF AND USE OF SAME - The invention relates to a pharmaceutical composition of vinflunine in the form of a stable sterile aqueous solution of a water-soluble salt of vinflunine with a pH of between 3 and 4. The invention also relates to the method of preparing said composition and to the use thereof as a parenterally-administered medicament for the treatment of cancer. | 01-20-2011 |
| 20110014122 | NOVEL ANTI-IGF-IR AND/OR ANTI-INSULIN/IGF-I HYBRID RECEPTORS ANTIBODIES AND USES THEREOF - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR) and/or the insulin/IGF-I hybrid receptor (hybrid-R) and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR and/or hybrid-R, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR and/or hybrid-R or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or hybrid-R. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 01-20-2011 |
| 20110003705 | NOVEL METHOD FOR GENERATING AND SCREENING AN ANTIBODY LIBRARY - The invention relates to a method for generating a DNA sequence coding for the heavy chain or the light chain of at least one antibody from RNA from a cell capable of producing an antibody. More particularly, the invention relates to the generation of a monoclonal antibody library. The invention also relates to the use of an antibody library for screening monoclonal antibodies, preferably human antibodies for treating cancer. | 01-06-2011 |
| 20100286284 | 5-[1'-(DECAHYDRO-7-HYDROXY-1,1,3A,7-TETRAMETHYL-1H-CYCLOPROPA[A]NAPHTHALEN- -4-YL)-3'-METHYLBUTYL]-2,4,6-TRIHYDROXY-1,3-BENZENEDICARBOXALDEHYDE AS MEDICAMENTS - The present invention relates to new compounds of formula (I) and to their use as medicaments. Preferably, the said compounds are used in the preparation of a medicament or food supplement intended for the treatment and/or prevention of ailments or pathologies ensuing from a disorder of the reuptake of the following neurotransmitters: dopamine, serotonin and/or noradrenaline. | 11-11-2010 |
| 20100280263 | Process for the Synthesis of Anticancer (Poly) Aminoalkylaminoacetamide Derivatives of Epipodophyllotoxin - The present invention describes a new process for the preparation of (poly)aminoalkylaminoacetamide compounds of epipodophyllotoxin useful for their applications in therapeutics as anticancer agents. This process comprises a step of condensation of a primary-amine-containing reactant, whose amine functions are not protected, with β-chloroacetamido-4′-epipodophyllotoxin in a polar aprotic organic solvent. | 11-04-2010 |
| 20100273752 | MEQUITAZINE FOR TREATING OR PREVENTING PATHOLOGIES INVOLVING HISTAMINE H4 RECEPTORS - The present application relates to the use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine, 10-[(3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine or 10-[(3R,3S)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine, or a pharmaceutically acceptable salt thereof, to prepare a drug to prevent or treat pathologies involving histamine H4 receptor. | 10-28-2010 |
| 20100266570 | DIMERIC DERIVATIVES OF ARTEMISININ AND APPLICATION IN ANTICANCER THERAPY - The present invention relates to dimeric derivatives of 10-trifluoromethylated artemisinin of formula (I): or a pharmaceutically acceptable salt thereof with B | 10-21-2010 |
| 20100202975 | NOVEL FLUORESCENT DERIVATIVES OF POLYAMINES, METHOD FOR PREPARING SAME AND APPLICATIONS THEREOF AS DIAGNOSIS TOOLS IN THE TREATMENT OF CANCEROUS TUMORS - The invention relates to novel fluorescent derivatives of polyamines having a benzoxadiazole group, to a method for preparing the same and to the use thereof as diagnosis tools for emphasising the polyamine transport system in cancerous cells in order to adapt the treatment thereof, and thus for selecting patients carrying such tumours in order to adapt their treatment. The derivatives are of the formula (I) or a pharmaceutically acceptable salt thereof, in which: R | 08-12-2010 |
| 20100196468 | STABLE PHARMACEUTICAL COMPOSITION COMPRISING A HYDROSOLUBLE VINFLUNINE SALT - Stable pharmaceutical composition consisting of a hydrosoluble vinflunine salt and at least one diluent and one lubricant, said composition being in the form of a solid intended for oral administration. The hydrosoluble vinflunine salt is preferably Vinflunine ditartrate. The pharmaceutical composition is advantageously in the form of a capsule or tablet. The invention also concerns a method of treating cancer pathology comprising the oral administration of the pharmaceutical composition of the invention. | 08-05-2010 |
| 20100196465 | STABLE PHARMACEUTICAL COMPOSITION OF A WATER-SOLUBLE VINORELBINE SALT - A stable pharmaceutical composition comprising a water-soluble vinorelbine salt and at least one diluent and one lubricant, characterized in that it appears in a solid form intended for oral administration. The water-soluble vinorelbine salt is advantageously vinorelbine ditartrate. The pharmaceutical composition advantageously appears as a gelatin capsule or tablet. | 08-05-2010 |
| 20100196363 | CANCER TREATMENT COMBINATION THERAPY COMPRISING VINFLUNINE AND TRASTUZUMAB - The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination comprising vinflunine and trastuzumab. | 08-05-2010 |
| 20100150935 | USE OF AN ANTI-CXCR4 ANTIBODY IN THE TREATMENT OF CANCER - The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the protein CXCR4 and thereby inhibiting tumour growth, in the preparation of a medicament intended for the treatment of cancer. | 06-17-2010 |
| 20100146650 | METHOD FOR GENERATING ACTIVE ANTIBODIES AGAINST A RESISTANCE ANTIGEN, ANTIBODIES OBTAINED BY SAID METHOD AND THEIR USES - The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer. | 06-10-2010 |
| 20100105897 | NOVEL QUINUCLIDINE DERIVATIVE USEFUL IN THE PREPARATION OF MEQUITAZINE - The invention relates to a 1-aza-bicyclo[2.2.2]oct-2-en-3-ylmethyl acetate of the formula (I), wherein said compound is useful as a synthesis intermediate for the production of mequitazine. | 04-29-2010 |
| 20100099709 | PYRIDIN-2-YL-METHYLAMINE DERIVATIVES FOR TREATING OPIATE DEPENDENCE - The invention concerns the use pf compounds of general formula (I) | 04-22-2010 |
| 20100093997 | FLUORINATED CATHARANTHINE DERIVATIVES, THEIR PREPARATION AND THEIR UTILISATION AS VINCA DIMERIC ALKALOID PRECURSORS - The fluorinated derivatives of catharanthine according to the invention respond to the general formula I: | 04-15-2010 |
| 20100092455 | NOVEL ANTI-PROLIFERATION ANTIBODIES - The present invention relates to novel isolated antibodies, or the derived compounds or functional fragments of same, capable of inhibiting the proliferation of tumor cells in vitro and/or in vivo, said antibodies having been obtained by functional screening. | 04-15-2010 |
| 20100087473 | FREEZE-DRIED INJECTABLE PHARMACEUTICAL COMBINATION OF SEMISYNTHETIC VINCA ALKALOIDS AND CARBOHYDRATE STABLE AT ROOM TEMPERATURE - This invention relates to pharmaceutical compositions consisting of a semisynthetic derivative of vinca alkaloid, stable at room temperature, in which said derivative is present in the form of a freeze dried product obtained in the presence of at least one carbohydrate. | 04-08-2010 |
| 20100087392 | COMPLEXES OF IBUPROFEN, CYCLODEXTRINS AND TERNARY AGENTS AND THE USE THEREOF IN PHARMACEUTICS - The present invention relates to pharmaceutical compositions comprising ibuprofen in the form of an ibuprofen/cyclodextrin/lysine complex having improved pharmacokinetic properties compared with ibuprofen alone, such as a shortened Tmax and an increased Cmax. | 04-08-2010 |
| 20100063276 | USE OF 10-[(3R)-1-AZABICYCLO[2.2.2]OCT-3-YLMETHYL]-10H-PHENOTHIAZINE FOR THE PREPARATION OF A DRUG HAVING A SELECTIVE INHIBITION OF MUSCARINIC M1, M2, AND M3 RECEPTORS - This invention relates to the use of 10-[(3R)-1-azabicyclo[2.2.2]oct-3-ylmethyl]-10H-phenothiazine as well as its pharmaceutically acceptable salts for the preparation of a drug having the particularity of treating or preventing urinary incontinence, by local and/or oral route. | 03-11-2010 |
| 20100041703 | RAPID DISINTEGRATION MONOLAYER FILM FOR THE ORAL ADMINISTRATION OF ACTIVE SUBSTANCES - Rapid-disintegration monolayer film for the oral administration of active substances, comprising a water-soluble support containing at least one active substance, characterized in that it comprises a polymeric mixture of a hydrophilic film-forming agent formed from a copolymer of polyvinyl alcohol and of polyethylene glycol (PVA-PEG), of an active substance and of a hydrophilic gelling agent. | 02-18-2010 |
| 20100029703 | ANHYDROUS CRYSTALLINE VINFLUNINE SALTS, METHOD OF PREPARATION AND USE THEREOF AS A DRUG AND MEANS OF VINFLUNINE PURIFICATION - The present invention relates to anhydrous crystalline vinflunine salts obtained with 1 or 2 equivalents of a pharmaceutically acceptable mineral or organic acid [Acid] 1 or 2 in which [Acid] represents hydrobromic, sulfuric, lactic and fumaric acids for the group of water-soluble crystalline salts, and para-toluene sulfonic, benzoic, mandelic and para-hydroxy benzoic acids for the group of relatively insoluble crystalline salts. | 02-04-2010 |
| 20090325984 | USE OF 1,7-DIMETHYLXANTHINE FOR THE MANUFACTURE OF A NON-ANXIOGENIC PSYCHOANALEPTIC DRUG FOR THE TREATMENT OF A NEUROPSYCHIATRIC DISORDER - The present invention relates to the use of paraxanthine for the manufacture of a non-anxiogenic psychoanaleptic drug for the treatment of a neuropsychiatric disorder. | 12-31-2009 |
| 20090324754 | EUCALYPTUS EXTRACT, METHOD OF PREPARATION AND THERAPEUTIC USES THEREOF - The present invention relates to the use of a | 12-31-2009 |
| 20090324600 | Use of an anti-cd151 antibody in the treatment of cancer - The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumour growth, in the preparation of a medicament intended for the treatment of cancer. | 12-31-2009 |
| 20090318709 | PROCESS FOR THE SYNTHESIS OF N-[3-[(2-METHOXYPHENYL] SULFANYL] -2-METHYLPROPYL] -3,4-DIHYDRO-2H-1,5-BENZOXATHIEPIN-3-AMINE. - The invention relates to a new process for the preparation of N-[3-[(2-methoxyphenyl)sulfanyl]-2-methylpropyl]-3,4-dihydro-2H-1,5-benzoxathiepin-3-amine. | 12-24-2009 |
| 20090318555 | Treatment of Vertigo with Acetyl-L-Leucine - The use of acetyl-L-leucine and the pharmaceutically acceptable salts of same for the manufacture of a medicament for the treatment of vertigo and other balance disorders. Advantageously, the acetyl-L-leucine is a 100% mixture. | 12-24-2009 |
| 20090312354 | DHA Esters and Use Thereof In Treatment and Prevention of Cardiovascular Disease - The present invention relates to a docosahexaenoic acid ester with an alcohol chosen among the group-B vitamins or provitamins, advantageously comprised by: nicotinyl alcohol of the following formula (I), panthenol of the following formula (II), and inositol of the following formula (III) or with isosorbide of the following formula (IV) or isosorbide mononitrate of the following formula (V). It also relates to a method of preparation of same, a pharmaceutical composition comprising same and the use of same in the treatment or prevention of cardiovascular disease, in particular auricular fibrillation. | 12-17-2009 |
| 20090298908 | DMAE AS SOLE AGENT FOR THE TREATMENT OF MILD COGNITIVE IMPAIRMENT - The present invention relates to the use, as sole active ingredient, of dimethylaminoethanol (DMAE) in free form or in the form of salts or of esters and also of hydrates and solvates thereof, for the manufacture of a medicament for use in the treatment of a non-dementia mild cognitive impairment characterized by an amnestic syndrome of hippocampal type. | 12-03-2009 |
| 20090265797 | Novel Anti-IGF-IR Antibodies and Uses Thereof - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor (IGF-IR). The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR, stimulated either by IGF1 and/or IGF2, or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR and/or the IGF-I/Insulin hybrid receptor. | 10-22-2009 |
| 20090124010 | Peptide Fractions Promoting Growth and Synthesis of Desired Product (S) Into Cell and/or Tissue Culture - The invention relates to preparing and/or supplementing a cell or tissue culture medium. In particular, said invention relates to a serum-free and/or protein-free cell culture medium comprising peptide fractions isolated from rapeseeds, in particular rapeseeds cakes. A method for the production of a cell culture comprising said peptide fractions and for the use thereof is also disclosed. | 05-14-2009 |
| 20090118507 | Method for Preparing (3-Chloro-4-Fluorophenyl)-(4-Fluoro-4--Piperidin-1-Yl)-Methanone and Novel Intermediate Pyrimidine Derivatives - The present invention concerns the method for preparing (3-chloro-4-fluorophenyl)-(4-fluoro-4-{[(5-methyl-pyrimidin-2-ylmethyl)-amino]-methyl}-piperidin-1-yl)-methanone of formula (II) by condensation between 5-methyl-pyrimidin-2-methylamine of formula (I) and cyanohydrin of formula (III). | 05-07-2009 |
| 20090082582 | Process For Preparing [2-(2,3- Dihydrobenzofuran - Or Benzofuran-7-Yloxy)Ethyl]-(3 -Cyclopent-1-Ylbenzyl)Amine Derivatives and Synthesis Intermediate - The invention relates to a process for the preparation of compounds of general formula (3) | 03-26-2009 |
| 20090082447 | Pharmaceutical Compositions Containing Omega 3 Fatty Acids - Pharmaceutical composition comprising a liquid oil rich in omega-3 polyunsaturated fatty acids which is absorbed on a silica-type support. The composition so obtained has the characteristics of a powder when the oil:silica ratio is of the order of 3:1 while at the same time allowing the required daily dose of omega-3 fatty acids to be delivered in one or more unit doses. The composition according to the invention can be used in the manufacture of oral pharmaceutical forms such as hard capsules. | 03-26-2009 |
| 20090069308 | Novel Use of Antihistamine Agents for the Preventive or Early Treatment of Inflammatory Syndromes, in Particular Those Triggered by Togaviruses - The present invention relates to the use of at least one antihistamine agent for the preparation of a medicament for use in the preventive or early treatment of inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses. The invention also relates to a combination product of at least one antihistamine agent and of at least one antiserotonin agent for its simultaneous, separate or sequential use in preventive or early therapy for inflammatory syndromes of viral origin, in particular arthritis of the distal joints, more particularly those triggered by togaviruses. | 03-12-2009 |
| 20090049935 | Stabilized milnacipran formulation - It is intended to provide a milnacipran formulation which is more stable than a conventionally known milnacipran formulation, and a method of stabilizing a milnacipran formulation. The object could be achieved by using a milnacipran-containing composition in which milnacipran or a salt thereof is allowed to exist in a porous carrier, packing a powder containing milnacipran or a salt thereof in an HPMC capsule, or combining an additive which does not cause an interaction with milnacipran with time. | 02-26-2009 |
| 20090042876 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors - The present invention relates to inhibitors of protein kinases of formula I: | 02-12-2009 |
| 20090036367 | Novel peptides of the respiratory syncytial virus (RSV) G protein and their use in a vaccine - The present invention relates to the Respiratory Syncytial Virus, and more particularly to the identification of novel antigens which are useful in particular for the therapeutic and prophylactic treatment of conditions caused by this virus. The present invention relates to methods of generating and/or increasing an immunogenic response directed against Respiratory Syncytial Virus, including subgroups A and B. | 02-05-2009 |
| 20080317859 | Stabilization of Testosterone Within Transdermal Devices - The present invention relates to the chemical stabilization of testosterone contained in self-adhesive transdermal devices by way of the association of a desiccant agent with said device within a sealing packaging. The use of a desiccant agent makes it possible to limit the chemical degradation of the testosterone to androstenedione and other impurities and accordingly ensures storage of said device over periods of up to thirty-six months. | 12-25-2008 |
| 20080300382 | Immunogenic Complexes, Preparation Method Thereof And Use Of Same In Pharmaceutical Compositions - The invention relates to a method of improving the immunogenicity of an immunogen, antigen or hapten, by means of coupling with a small support peptide. More specifically, the invention relates to a method of preparing an immunogenic complex, as well as the complexes that can be obtained using one such method, and to the use of said complexes as a medicament in order to increase the immunogenicity of an immunogen. The invention comprises, for example, a support peptide which is coupled with a peptide from protein G of the respiratory syncytial virus (RSV) and to the use thereof as a vaccine for the treatment of respiratory infections linked to RSV. | 12-04-2008 |
| 20080286198 | Novel anti-IGF-IR antibodies and uses thereof - The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers. | 11-20-2008 |
| 20080260828 | STABLE SOLID DISPERSION OF A DERIVATIVE OF VINCA ALKALOID AND PROCESS FOR MANUFACTURING IT - This invention relates to solid and stable dispersions of a hydrosoluble derivative of vinca alkaloids in at least one polyethyleneglycol with a molecular mass between 800 and 30,000. | 10-23-2008 |
